Additional studies are now required to develop neutralizing antibodies against relevant circulating S100 isoforms aberrantly expressed with NAFLD/NASH and liver cancers, e.g., S100A4 and S100A11, and to investigate in vivo their therapeutic potential prior to envisaging their use in clinical settings. The gene discussed is S100A11; the disease is metabolic dysfunction-associated steatotic liver disease.